First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $26M — +413445% growth in a single year.
What Moves the Stock
1Pemvidutide Phase 2 MOMENTUM trial data readouts - weight loss efficacy, safety profile, and liver biomarker improvements versus Wegovy/Zepbound benchmarks
2Clinical trial enrollment milestones and timeline updates for obesity and MASH indications
3Partnership announcements or licensing deals with major pharma (Novo Nordisk, Eli Lilly, Pfizer, Amgen) for commercialization rights
4Equity financing announcements and cash runway extensions - critical given $100M+ annual burn and $72M cash position (estimated Q4 2025)
5Competitive landscape developments in GLP-1 market - oral formulations, next-gen dual/triple agonists, pricing pressure from biosimilars
6No current commercial revenue - pre-revenue clinical stage
7Historical grant revenue (discontinued, explaining -95.3% revenue decline)
8Future potential: pemvidutide royalties/product sales if approved (estimated 2028+ timeline)
High-risk growth and momentum investors seeking asymmetric biotech binary events.
High sensitivity through multiple mechanisms.
Watch on earnings: Pemvidutide Phase 2 MOMENTUM trial topline data release timing and weight loss results versus 15% efficacy threshold, Cash and cash equivalents quarterly burn rate and runway to next financing event, Novo Nordisk and Eli Lilly quarterly GLP-1 sales growth and market share trends as proxy for total addressable market expansion.
One Sentence Summary:
Altimmune: the story is balanced — pemvidutide phase 2 momentum trial data readouts - weight loss efficacy, safety profile.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.